{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T04:54:13Z","timestamp":1791089653971,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006453","name":"Taisho Toyama Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Sleep Medicine"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.sleep.2026.109260","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T16:24:46Z","timestamp":1788971086000},"page":"109260","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Long-term safety and efficacy of vornorexant in Japanese patients with insomnia: A 52-week open-label, randomized trial"],"prefix":"10.1016","volume":"148","author":[{"given":"Naohisa","family":"Uchimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5134-3554","authenticated-orcid":false,"given":"Daiji","family":"Kambe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayaka","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Imadera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1727-7405","authenticated-orcid":false,"given":"Hironori","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Uchiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.sleep.2026.109260_bib1","series-title":"International classification of sleep disorders \u2013third edition (ICSD-3). AASM resour libr","year":"2014"},{"issue":"11","key":"10.1016\/j.sleep.2026.109260_bib2","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.18782","article-title":"Incidence, persistence, and remission rates of insomnia over 5 years","volume":"3","author":"Morin","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"11","key":"10.1016\/j.sleep.2026.109260_bib3","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/hr.2013.70","article-title":"The relationship of sleep duration and insomnia to risk of hypertension incidence: a meta-analysis of prospective cohort studies","volume":"36","author":"Meng","year":"2013","journal-title":"Hypertens Res"},{"issue":"11","key":"10.1016\/j.sleep.2026.109260_bib4","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.2337\/dc09-0284","article-title":"Insomnia with objective short sleep duration is associated with type 2 diabetes: a population-based study","volume":"32","author":"Vgontzas","year":"2009","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.sleep.2026.109260_bib5","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1186\/s12888-016-1075-3","article-title":"Insomnia and the risk of depression: a meta-analysis of prospective cohort studies","volume":"16","author":"Li","year":"2016","journal-title":"BMC Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.sleep.2026.109260_bib6","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jad.2011.01.011","article-title":"Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies","volume":"135","author":"Baglioni","year":"2011","journal-title":"J Affect Disord"},{"issue":"7","key":"10.1016\/j.sleep.2026.109260_bib7","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/sleep\/30.7.873","article-title":"Chronic insomnia as a risk factor for developing anxiety and depression","volume":"30","author":"Neckelmann","year":"2007","journal-title":"Sleep"},{"issue":"2","key":"10.1016\/j.sleep.2026.109260_bib8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.7326\/M15-2175","article-title":"Clinical guidelines committee of the American college of physicians. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American college of physicians","volume":"165","author":"Qaseem","year":"2016","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.sleep.2026.109260_bib9","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsaf291","article-title":"Efficacy and safety of vornorexant in Japanese patients with insomnia: a randomized, placebo-controlled phase 3 pivotal study","volume":"49","author":"Uchiyama","year":"2025","journal-title":"Sleep"},{"issue":"13","key":"10.1016\/j.sleep.2026.109260_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115489","article-title":"Discovery of ORN0829, a potent dual orexin 1\/2 receptor antagonist for the treatment of insomnia","volume":"28","author":"Futamura","year":"2020","journal-title":"Bioorg Med Chem"},{"issue":"7","key":"10.1016\/j.sleep.2026.109260_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpet.2025.103624","article-title":"Preclinical pharmacological profiles of vornorexant, a novel potent dual orexin receptor antagonist","volume":"392","author":"Hikichi","year":"2025","journal-title":"J Pharmacol Exp Therapeut"},{"issue":"5","key":"10.1016\/j.sleep.2026.109260_bib12","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/bcpt.13930","article-title":"Pharmacokinetics, pharmacodynamics and safety profile of the dual orexin receptor antagonist vornorexant\/TS-142 in healthy Japanese participants following single\/multiple dosing: randomized, double-blind, placebo-controlled phase-1 studies","volume":"133","author":"Kambe","year":"2023","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"2","key":"10.1016\/j.sleep.2026.109260_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.1183","article-title":"Preclinical metabolism and the disposition of vornorexant\/TS-142, a novel dual orexin 1\/2 receptor antagonist for the treatment of insomnia","volume":"12","author":"Konno","year":"2024","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.sleep.2026.109260_bib14","series-title":"Bridgewater: Sanofi-aventis","year":"2022"},{"key":"10.1016\/j.sleep.2026.109260_bib15","series-title":"Marlborough","year":"2019"},{"key":"10.1016\/j.sleep.2026.109260_bib16","series-title":"Diagnostic and statistical manual of mental disorders: DSM-5","year":"2013"},{"issue":"4","key":"10.1016\/j.sleep.2026.109260_bib17","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1389-9457(00)00065-4","article-title":"Validation of the Insomnia Severity Index as an outcome measure for insomnia research","volume":"2","author":"Bastien","year":"2001","journal-title":"Sleep Med"},{"issue":"3","key":"10.1016\/j.sleep.2026.109260_bib18","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0165-1781(02)00106-3","article-title":"Cross-cultural validation of the Beck Depression Inventory-II in Japan","volume":"110","author":"Kojima","year":"2002","journal-title":"Psychiatry Res"},{"issue":"6","key":"10.1016\/j.sleep.2026.109260_bib19","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1037\/0022-006X.56.6.893","article-title":"An inventory for measuring clinical anxiety: psychometric properties","volume":"56","author":"Beck","year":"1988","journal-title":"J Consult Clin Psychol"},{"issue":"12","key":"10.1016\/j.sleep.2026.109260_bib20","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults","volume":"168","author":"Posner","year":"2011","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10.1016\/j.sleep.2026.109260_bib21","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0165-0327(90)90009-W","article-title":"The benzodiazepine withdrawal symptom questionnaire","volume":"19","author":"Tyrer","year":"1990","journal-title":"J Affect Disord"},{"issue":"11","key":"10.1016\/j.sleep.2026.109260_bib22","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/j.1552-4604.1990.tb03592.x","article-title":"Clinical evaluation of diphenhydramine hydrochloride for the treatment of insomnia in psychiatric patients: a double-blind study","volume":"30","author":"Kudo","year":"1990","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.sleep.2026.109260_bib23","first-page":"1836","article-title":"A 1,4-benzodiazepine, temazepam (K 3917), its effect on some psychological parameters of sleep and behaviour","volume":"25","author":"Hindmarch","year":"1975","journal-title":"Arzneim Forsch"},{"issue":"1","key":"10.1016\/j.sleep.2026.109260_bib24","first-page":"24m03810","article-title":"Effect of lemborexant on daytime functioning in adults with insomnia: patient-reported outcomes from a phase 3 clinical trial","volume":"27","author":"Chepke","year":"2025","journal-title":"Prim Care Companion CNS Disord"},{"issue":"7","key":"10.1016\/j.sleep.2026.109260_bib25","first-page":"28","article-title":"The clinical global impressions scale: applying a research tool in clinical practice","volume":"4","author":"Busner","year":"2007","journal-title":"Psychiatry (Edgmont)"},{"issue":"Suppl 3","key":"10.1016\/j.sleep.2026.109260_bib26","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00004850-199606003-00015","article-title":"The measurement of disability","volume":"11","author":"Sheehan","year":"1996","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.sleep.2026.109260_bib27","article-title":"International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use","year":"1994","journal-title":"ICH harmonised tripartite guideline: the extent of population exposure to assess clinical safety for drugs intended for long-term treatment of non-life-threatening conditions\u2014E1"},{"issue":"7","key":"10.1016\/j.sleep.2026.109260_bib28","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1007\/s00213-022-06089-6","article-title":"Effects of TS-142, a novel dual orexin receptor antagonist, on sleep in patients with insomnia: a randomized, double-blind, placebo-controlled phase 2 study","volume":"239","author":"Uchiyama","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"issue":"11","key":"10.1016\/j.sleep.2026.109260_bib29","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/pcn.13888","article-title":"Driving performance in the morning after bedtime vornorexant administration: a randomized clinical trial using a driving simulator","volume":"79","author":"Miyazaki","year":"2025","journal-title":"Psychiatr Clin Neurosci"},{"issue":"5","key":"10.1016\/j.sleep.2026.109260_bib30","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S1474-4422(14)70053-5","article-title":"Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial","volume":"13","author":"Michelson","year":"2014","journal-title":"Lancet Neurol"},{"issue":"7","key":"10.1016\/j.sleep.2026.109260_bib31","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/sleep\/26.7.793","article-title":"Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia","volume":"26","author":"Krystal","year":"2003","journal-title":"Sleep"},{"issue":"6","key":"10.1016\/j.sleep.2026.109260_bib32","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.sleep.2005.06.004","article-title":"An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia","volume":"6","author":"Roth","year":"2005","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2026.109260_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.1070522","article-title":"Dual orexin receptor antagonists for treatment of insomnia: a systematic review and meta-analysis on randomized, double-blind, placebo-controlled trials of suvorexant and lemborexant","volume":"13","author":"Khazaie","year":"2022","journal-title":"Front Psychiatr"},{"key":"10.1016\/j.sleep.2026.109260_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1175372","article-title":"Different doses of dual orexin receptor antagonists in primary insomnia: a Bayesian network analysis","volume":"14","author":"Xue","year":"2023","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.sleep.2026.109260_bib35","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1093\/ije\/dyu115","article-title":"Bias due to lack of patient blinding in clinical trials. A systematic review of trials randomizing patients to blind and nonblind sub-studies","volume":"43","author":"Hr\u00f3bjartsson","year":"2014","journal-title":"Int J Epidemiol"},{"issue":"12","key":"10.1016\/j.sleep.2026.109260_bib36","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1056\/NEJMra1611832","article-title":"Treatment of benzodiazepine dependence","volume":"376","author":"Soyka","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.sleep.2026.109260_bib37","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/00004850-199909000-00004","article-title":"Tolerance and rebound insomnia with rapidly eliminated hypnotics: a meta-analysis of sleep laboratory studies","volume":"14","author":"Soldatos","year":"1999","journal-title":"Int Clin Psychopharmacol"},{"issue":"9","key":"10.1016\/j.sleep.2026.109260_bib38","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.2105\/AJPH.83.9.1300","article-title":"The dependence potential of short half-life benzodiazepines: a meta-analysis","volume":"83","author":"Hallfors","year":"1993","journal-title":"Am J Publ Health"},{"key":"10.1016\/j.sleep.2026.109260_bib39","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.2147\/JPR.S210502","article-title":"Efficacy and safety of controlled-release oxycodone for the management of moderate-to-severe chronic non-cancer pain in Japanese patients: results from an open-label study","volume":"12","author":"Kawamata","year":"2019","journal-title":"J Pain Res"},{"issue":"3","key":"10.1016\/j.sleep.2026.109260_bib40","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.psychres.2015.11.003","article-title":"Prevalence and associated factors of hypnotics dependence among Japanese outpatients with psychiatric disorders","volume":"230","author":"Murakoshi","year":"2015","journal-title":"Psychiatry Res"},{"issue":"1","key":"10.1016\/j.sleep.2026.109260_bib41","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/s41398-024-03087-4","article-title":"Orexin receptor antagonists in the treatment of insomnia associated with psychiatric disorders: a systematic review","volume":"14","author":"Kishi","year":"2024","journal-title":"Transl Psychiatry"},{"issue":"7282","key":"10.1016\/j.sleep.2026.109260_bib42","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nature08758","article-title":"Neural bases for addictive properties of benzodiazepines","volume":"463","author":"Tan","year":"2010","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.sleep.2026.109260_bib43","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0005-7967(02)00023-2","article-title":"Quantitative criteria for insomnia","volume":"41","author":"Lichstein","year":"2003","journal-title":"Behav Res Ther"},{"issue":"2","key":"10.1016\/j.sleep.2026.109260_bib44","doi-asserted-by":"crossref","first-page":"307","DOI":"10.5664\/jcsm.6470","article-title":"Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American academy of sleep medicine clinical practice guideline","volume":"13","author":"Sateia","year":"2017","journal-title":"J Clin Sleep Med"},{"key":"10.1016\/j.sleep.2026.109260_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.smrv.2020.101332","article-title":"Effects of orexin receptor antagonism on human sleep architecture: a systematic review","volume":"53","author":"Clark","year":"2020","journal-title":"Sleep Med Rev"},{"issue":"2","key":"10.1016\/j.sleep.2026.109260_bib46","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1053\/smrv.2002.0186","article-title":"Epidemiology of insomnia: what we know and what we still need to learn","volume":"6","author":"Ohayon","year":"2002","journal-title":"Sleep Med Rev"},{"key":"10.1016\/j.sleep.2026.109260_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2020.577429","article-title":"Gender difference in the prevalence of insomnia: a meta-analysis of observational studies","volume":"11","author":"Zeng","year":"2020","journal-title":"Front Psychiatr"},{"key":"10.1016\/j.sleep.2026.109260_bib48","doi-asserted-by":"crossref","first-page":"zsaa123","DOI":"10.1093\/sleep\/zsaa123","article-title":"Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2","author":"Karppa","year":"2020","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2026.109260_bib49","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.sleep.2024.07.036","article-title":"Long-term safety and efficacy of daridorexant in Japanese patients with insomnia disorder","volume":"122","author":"Uchimura","year":"2024","journal-title":"Sleep Med"},{"issue":"1","key":"10.1016\/j.sleep.2026.109260_bib50","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s40263-022-00980-8","article-title":"Long-term safety and tolerability of daridorexant in patients with insomnia disorder","volume":"37","author":"Kunz","year":"2023","journal-title":"CNS Drugs"},{"key":"10.1016\/j.sleep.2026.109260_bib51","doi-asserted-by":"crossref","DOI":"10.1007\/s00213-026-07095-8","article-title":"Comparison of next-morning residual effects by bedtime administration of vornorexant and zopiclone in healthy older participants: postural stability, neuropsychological functions, and subjective sleepiness in a randomized clinical study","author":"Miyazaki","year":"2026","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"10.1016\/j.sleep.2026.109260_bib52","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1146\/annurev-pharmtox-040323-031929","article-title":"Orexin receptor antagonism: normalizing sleep architecture in old age and disease","volume":"64","author":"Kron","year":"2024","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.sleep.2026.109260_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.smrv.2021.101573","article-title":"The efficacy and safety of dual orexin receptor antagonists in primary insomnia: a systematic review and network meta-analysis","volume":"61","author":"Xue","year":"2022","journal-title":"Sleep Med Rev"},{"issue":"8","key":"10.1016\/j.sleep.2026.109260_bib54","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1007\/s00213-025-06773-3","article-title":"Comparison of efficacy and safety of dual orexin receptor antagonists lemborexant and daridorexant for the treatment of insomnia: a systematic review and meta-analysis","volume":"242","author":"Tang","year":"2025","journal-title":"Psychopharmacology (Berl)"}],"container-title":["Sleep Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1389945726004995?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1389945726004995?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T04:21:02Z","timestamp":1791087662000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1389945726004995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":54,"alternative-id":["S1389945726004995"],"URL":"https:\/\/doi.org\/10.1016\/j.sleep.2026.109260","relation":{},"ISSN":["1389-9457"],"issn-type":[{"value":"1389-9457","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term safety and efficacy of vornorexant in Japanese patients with insomnia: A 52-week open-label, randomized trial","name":"articletitle","label":"Article Title"},{"value":"Sleep Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sleep.2026.109260","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109260"}}